Topadur Pharma

Topadur Pharma is a private, clinical-stage biotech targeting age-related diseases driven by microvascular dysfunction. Its core asset is the DualTOP® platform, which employs a dual mechanism to induce vasodilation and angiogenesis for localized tissue regeneration. The pipeline features two lead programs, TOP-N53 for digital ulcers and diabetic foot ulcers and TOP-M119 for androgenetic alopecia, both advancing through Phase 2. The company follows a capital-efficient, partnership-driven strategy to advance its assets through proof-of-concept trials.

DualTOP® platform modulating cGMP to induce vasodilation and angiogenesis (new blood vessel formation) for localized tissue regeneration.

Topadur competes in crowded spaces: diabetic foot ulcer treatments include advanced wound care products, growth factors, and cell therapies, while alopecia has both generic drugs and novel agents in development. Its differentiation lies in its first-in-class mechanism targeting underlying microcirculation, a approach less common among direct competitors.